{
  "dataset": "nr-cost-by-brand",
  "title": "Nicotinamide Riboside (NR) Supplements Compared — cost per mg, the only two ASIN-gate-verified live products",
  "sourcePage": "https://verifiedsupplementdata.com/nr/best-overall/",
  "license": "CC-BY-4.0",
  "licenseUrl": "https://creativecommons.org/licenses/by/4.0/",
  "attribution": "Verified Supplement Data (2026), NR Cost Comparison",
  "dateModified": "2026-07-18",
  "methodology": "Both products here disclose NR mg directly on the label, so cost per mg is a computable comparison: costPerMg = price / (servings x mg per serving). This ASIN-gate pass (2026-07-18) checked several additional generic NR listings and found them out of stock or delisted — a near-duopoly, not a curated shortlist, which is why only two products appear. \"niagenBranded\" flags the ChromaDex/Niagen Bioscience ingredient (Tru Niagen) behind Conze 2019's manufacturer-run dose-response/safety trial; the other product (Thorne NiaCel 400) uses Thorne's own NR hydrogen malate form and is NSF Certified for Sport, third-party tested. Both products' per-serving dose (300mg and ~415mg) is BELOW the 1000mg/day dose most independent functional trials (Martens 2018, Elhassan 2019, NADPARK 2022) actually used — a real gap between the retail dose and the trial dose, disclosed here rather than implied away. EVIDENCE CONTEXT (short-term human RCTs only; no anti-aging, lifespan, or disease-treatment claim implied or supported): Conze 2019 (PMID 31278280) is ChromaDex's own manufacturer-run dose-response/safety trial (100/300/1000mg/day, NAD+ up 22/51/142%) — disclose this conflict of interest every time it is cited. Five independent, non-industry trials (Martens 2018 PMID 29599478, Dollerup 2018 PMID 29992272, Dollerup 2020 PMID 31710095, Elhassan 2019 PMID 31412242, Wang 2022 PMID 36644285) each tested a different organ system and each found the functional/clinical endpoint null or explicitly underpowered while NAD+ still rose. NADPARK (Brakedal 2022, PMID 35235774) is a Phase I, n=30, 30-day safety trial in Parkinson's disease — never cite as \"NR treats Parkinson's.\" The 2021 ChromaDex/Thorne patent suit over the NiaCel product was dismissed Jan 2024 after the underlying NR composition-of-matter patents were ruled patent-ineligible in a related Federal Circuit case — resolved history, not a live dispute. This statement has not been evaluated by the FDA; these products are not intended to diagnose, treat, cure, or prevent any disease.",
  "headline": {
    "productsCompared": 2,
    "conzeMidDoseMg": 300,
    "functionalTrialMg": 1000,
    "highDoseTrialMg": 2000,
    "cheapestPerMg": 0.003,
    "cheapestPerMgBrand": "Thorne",
    "niagenBrandedBrand": "Tru Niagen",
    "nonNiagenBrand": "Thorne",
    "note": "Only two products cleared the live-price ASIN gate; several generic NR listings checked were out of stock or delisted. Both live products are below the 1,000mg/day dose most functional trials used."
  },
  "columns": [
    "brand",
    "product",
    "slug",
    "form",
    "mgPerServing",
    "servings",
    "price",
    "costPerServing",
    "costPerDay",
    "costPerMg",
    "niagenBranded",
    "verdict",
    "thirdParty"
  ],
  "units": {
    "mgPerServing": "mg NR",
    "price": "USD",
    "costPerServing": "USD/serving",
    "costPerDay": "USD/day",
    "costPerMg": "USD per mg of NR"
  },
  "citations": [
    {
      "claim": "RCT, 8 weeks, dose-ranging 100/300/1000mg/day: whole-blood NAD+ rose dose-dependently (22%/51%/142%); no flushing; no significant AE vs placebo. ChromaDex's own manufacturer-run trial of its own branded ingredient — highest conflict of interest in this evidence base.",
      "source": "Conze, Brenner & Kruger 2019, Scientific Reports",
      "pmid": "31278280"
    },
    {
      "claim": "RCT crossover, n=24, 1000mg/day, 6 weeks: NAD+ metabolome rose in PBMCs; systolic blood pressure and arterial stiffness trended down but were NOT statistically significant after correction in the whole group. Academic, NIH-funded.",
      "source": "Martens et al. 2018, Nature Communications",
      "pmid": "29599478"
    },
    {
      "claim": "RCT, n=40 obese men, 2000mg/day, 12 weeks: no improvement in insulin sensitivity, glucose disposal, or lipid/energy measures. Academic, non-industry.",
      "source": "Dollerup et al. 2018, Am J Clin Nutr",
      "pmid": "29992272"
    },
    {
      "claim": "Muscle-biopsy sub-study of the same cohort: no change in mitochondrial respiration, content, or morphology vs placebo.",
      "source": "Dollerup et al. 2020, J Physiol",
      "pmid": "31710095"
    },
    {
      "claim": "RCT crossover, n=12 aged men, 1000mg/day, 21 days: muscle NAD+ metabolome rose; mitochondrial bioenergetics (actual respiration) unaltered despite transcriptomic changes.",
      "source": "Elhassan et al. 2019, Cell Reports",
      "pmid": "31412242"
    },
    {
      "claim": "Phase I RCT, n=30 newly-diagnosed Parkinson's patients, 1000mg/day, 30 days: cerebral NAD+ rose; 'mild clinical improvement' was exploratory/correlational, not a powered efficacy result. Never cite as 'NR treats Parkinson's.'",
      "source": "Brakedal et al. 2022 (NADPARK), Cell Metabolism",
      "pmid": "35235774"
    },
    {
      "claim": "RCT, n=30 HFrEF patients, 2000mg/day, 12 weeks: NAD+ ~doubled; no significant between-group difference in 6-minute walk distance, LVEF, or quality of life. Authors state the trial was underpowered (would need ~172 participants for LVEF).",
      "source": "Wang et al. 2022, JACC: Basic to Translational Science",
      "pmid": "36644285"
    }
  ],
  "products": [
    {
      "brand": "Thorne",
      "product": "NiaCel 400",
      "slug": "thorne-niacel-400",
      "form": "Capsule (NR hydrogen malate)",
      "mgPerServing": 415,
      "servings": 60,
      "price": 74,
      "costPerServing": 1.23,
      "costPerDay": 1.23,
      "costPerMg": 0.003,
      "niagenBranded": false,
      "verdict": "retail-dose",
      "thirdParty": "NSF Certified for Sport; third-party tested. Thorne's own NR hydrogen malate form, not Niagen-branded.",
      "note": "Thorne's own NR hydrogen malate form, NOT Niagen-branded. NSF Certified for Sport, third-party tested. The 2021 ChromaDex/Thorne patent suit over this exact product was dismissed Jan 2024 — resolved history, not a live dispute."
    },
    {
      "brand": "Tru Niagen",
      "product": "300mg",
      "slug": "tru-niagen-300mg",
      "form": "Capsule",
      "mgPerServing": 300,
      "servings": 30,
      "price": 49,
      "costPerServing": 1.63,
      "costPerDay": 1.63,
      "costPerMg": 0.0054,
      "niagenBranded": true,
      "verdict": "retail-dose",
      "thirdParty": "Niagen-branded (ChromaDex/Niagen Bioscience) — the exact ingredient behind Conze 2019's manufacturer-run dose-response/safety trial",
      "note": "Niagen-branded (ChromaDex/Niagen Bioscience) — the exact ingredient behind Conze 2019's dose-response/safety trial. Flagship retail dose, but below the 1,000mg used in most functional trials."
    }
  ]
}